Novavax

Novavax, Inc. focuses on the discovery, development and commercialization of vaccines to prevent infectious diseases. It provides vaccines for COVID-19, seasonal flu, respiratory syncytial virus, Ebola, and Middle East respiratory syndrome. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novavax reports strong revenue growth, focuses on fall vaccine launch

Novavax aims to deliver a competitive vaccine for the fall season, optimize cash flow, and mitigate risks. The company's focus on cost reduction and strategic investments align with its goal of long-term growth.

Novavax reports positive Phase 2 results and revenue guidance

Novavax's Q1 2023 earnings call highlighted positive Phase 2 trial results, revenue guidance, and cost-saving initiatives.
The company's focus on vaccine development, workforce reductions, and strategic collaborations bode well for future growth.
Challenges include ongoing arbitration with Gavi and managing global restructuring impacts on R&D efforts.
Opportunities lie in revenue growth, market expansion with Nuvaxovid, and leveraging technology for a robust vaccine portfolio.

Novavax reports robust Q2 earnings, anticipates strong revenue growth

Novavax is on track to deliver an updated vaccine for the fall season and expects strong revenue growth in 2023. They have significantly reduced liabilities, signed key agreements, and are investing in combination vaccines. Despite challenges ahead, the company remains committed to delivering successful performance.

Novavax reports strong Q3 results, eyes market share growth

Novavax is strategically positioned to drive long-term profitability with efficient cost structures.
The company's focus on innovation, cost reduction, and market expansion bodes well for future growth.
Despite challenges, Novavax's strong financial position and technology platform offer resilience and growth opportunities.

Novavax reduces expenses, targets growth with new vaccines in 2024

Novavax made significant strides in reducing expenses and liabilities in 2023, positioning for growth in 2024.
The company's focus on advancing its combination vaccine program and improving market share presents opportunities for expansion.
Challenges include improving U.S. market performance, addressing remaining liabilities, and securing regulatory authorizations.
Efforts to streamline operations, enhance customer engagement, and offer convenient products are key to Novavax's success in 2024.

Novavax reports strong Q1 earnings, secures $1.3B Sanofi deal

Novavax's Q1 2024 performance shows promising revenue growth, expense reduction, and strategic partnership with Sanofi driving cash flow improvements.
While facing challenges in managing the multibillion-dollar opportunity and regulatory pathways, Novavax is well-positioned to capitalize on revenue opportunities.
The company's focus on optimizing existing agreements, expanding partnerships, and exploring new areas like RSV sets a strong foundation for future growth.

Novavax reports $85M revenue, focuses on cost reduction and partnerships

Novavax's Q3 2024 performance showcased revenue growth and strategic cost reduction efforts.
Key strengths include a strong partnership with Sanofi and a focus on pipeline development.
Challenges ahead involve cost alignment, trial design complexities, and maintaining margins.
Opportunities lie in new pipeline programs, financial gains from partnerships, and cost optimization.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax stock surely made millionaires in the past as it rose more than 2,700% back in 2020. Today, the stock has fallen more than 90% from its peak as the company faces various challenges.

Could Novavax Stock Help You Become a Millionaire?

Biotechnology firm Novavax (NASDAQ: NVAX )– which specializes in developing and commercializing next-generation vaccines — just announced a fresh round of job cuts. Earlier today, management said that it would reduce its global staff by about 12%.

Novavax Layoffs 2024: What to Know About the Latest NVAX Job Cuts

Vaccine maker Novavax said on Wednesday it will reduce its total global workforce by about 12% as part of its ongoing efforts to reduce costs.

Novavax to cut 12% of global workforce

Lexicon Pharmaceuticals

Plug Power

Pockets of optimism can always be found among Wall Street analysts. Three off-the-radar stocks could deliver jaw-dropping gains in 2024, based on the high-water price targets of three analysts.

3 Under-the-Radar Stocks With 340% to 762% Upside in 2024, According to Select Wall Street Analysts

Novavax's coronavirus vaccine may be more effective than others. But there isn't much demand anymore, and the biotech's overhead is high.

1 Reason to Buy Novavax Stock, and 3 (Better) Reasons to Sell

Novavax shares soared earlier in the pandemic, but they've dropped 98% from their peak. The company faces challenges, but it still could win over time in the post-pandemic vaccine market.

1 Reason to Buy Novavax Stock Hand Over Fist and 1 Reason to Sell

Novavax stock remains under pressure despite winning a key designation for its malaria shot. Is NVAX stock a buy or a sell in January 2024?

Is Novavax Stock A Buy After Winning A Key Designation From The World Health Organization?

Novavax was an early pandemic success story, surging more than 2,000% as investors bet on its coronavirus vaccine. But when the vaccine fell behind, the stock tumbled and hasn't yet recovered.

Novavax Stock May Soar 379%, According to Wall Street. Is the Stock a Buy Right Now?

GameStop

Lucid Group

One secret to making money in the markets is to keep holding winners and exit the losers as soon as a red flag appears. Investors need to keep aside biases and ego if the target is to make wealth from the markets.

Are You Kidding Me? 3 Meme Stocks You Should Have Already Sold

AMC Entertainment

Following last year's big rally, the stock market is off to a slow start in 2024. After two weeks the S&P 500 index is essentially flat.

Time to Buy These 3 Stocks That Just Hit a 52-Week Low?

Novavax, Inc. (NVAX) CEO John Jacobs Presents at JPMorgan 42nd Annual Healthcare Conference Transcript

JD.com

Petco Health and Wellness

Wall Street delivered a banner year in 2023, with the Dow hitting an all-time high and the Nasdaq Composite surging 43%. Despite big gains for the broader market, some high-flying stocks remain well below their peaks.

3 Turnaround Stocks With 151% to 600% Upside in 2024, According to Select Wall Street Analysts

GAITHERSBURG, Md. , Jan. 3, 2024 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that it will participate in the 42th Annual J.P.

Novavax to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Fastly

Fiverr

Match Group

Pubmatic

StoneCo

Wall Street produced stellar gains in 2023, with the growth-focused Nasdaq Composite rallying 43%. This year is shaping up to be a stock picker's market.

7 Magnificent Stocks That Can Double Your Money in 2024

C3.ai

Biomea Fusion Inc

Beyond Meat

Carvana

Fisker Inc

B. Riley Financial

Trupanion

Frontier Group Holdings

Upstart Holdings

The number of shorted shares has grown 23% since the end of 2020, but that doesn't mean traders are getting more bearish about the market.

Short Sellers Think These Stocks Will Tank in 2024. Investors Can Bet Otherwise.

Nikola

Rivian Automotive

Terawulf

As a critical mass of risk-hungry traders now believe “the coast is clear,” now may be the perfect time to consider which meme stocks to short. What do I mean by “the coast is clear?

Smart Shorts: 7 Meme Stocks to Bet Against in 2024

ChargePoint Holdings

There was a time when investors used to avoid heavily shorted stocks. Building-up of short interest indicates a bearish view of the stock, translating into a sustained correction.

3 Heavily Shorted Stocks That Still Won't See a Squeeze

Novavax stock jumped this month as the company launched its updated Covid shot abroad. Is NVAX stock a buy or a sell right now?

Is Novavax Stock A Buy On Its Covid Vaccine Launch Spree?

Novavax's updated vaccine will be available at vaccination centers across Taiwan GAITHERSBURG, Md. , Dec. 18, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid™ XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.

Novavax's Updated COVID-19 Vaccine Receives Emergency Use Authorization in Taiwan

During the meme stocks rally of 2021, it seemed that all potential meme stocks skyrocketed. The speculative activity peaked, and short-squeeze rallies delivered multi-bagger returns in weeks.

3 Meme Stocks That Could Fade Away in 2024

Novavax said on Tuesday that Health Canada had authorized its updated COVID-19 vaccine, targeting the Omicron subvariant XBB.1.5, in individuals aged 12 years and older.

Health Canada authorizes Novavax's updated COVID shot for Omicron

Novavax's updated protein-based non-mRNA COVID-19 vaccine will be available in Canada for individuals aged 12 and older in the coming days GAITHERSBURG, Md. , Dec. 5, 2023 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Health Canada has granted expanded authorization for Nuvaxovid™ XBB.1.5 Vaccine (Recombinant protein, Adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals aged 12 and older.

Novavax's Updated COVID-19 Vaccine Now Authorized in Canada

Novavax's prospects in the COVID-19 vaccine market look uncertain. The rest of the company's pipeline doesn't look inspiring.

Is Novavax Stock a Buy Now?

SunPower

Short squeezes, which are characterized by sudden and substantial surges in asset prices, have become prominent and debated phenomena on Wall Street in recent years. A short squeeze occurs when a high number of traders who shorted a given instrument are compelled to close their positions, ultimately pushing the asset's price higher.

3 Short-Squeeze Stocks That Could Take Off Before Year-End

Moderna

Pfizer

The one thing that experts, along with vaccine makers, can agree on is that low vaccination rates put people at risk of getting severe Covid infections.

News for Novavax Stock (NVAX)